Ashley Bush

List of Publications by Year in Descending Order

503 papers	53,921 citations	114 h-index	222 g-index
571 ext. papers	60,732 ext. citations	7.4 avg, IF	7.72 L-index

#	Paper	IF	Citations
503	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease.. *Proteome Science*, **2022**, 20, 2	2.6	1
502	APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.. *Alzheimer's and Dementia*, **2022**,	1.2	2
501	Neuropathological Mechanisms of β-N-Methylamino-L-Alanine (BMAA) with a Focus on Iron Overload and Ferroptosis.. *Neurotoxicity Research*, **2022**, 1	4.3	0
500	Selenium mediates exercise-induced adult neurogenesis and reverses learning deficits induced by hippocampal injury and aging.. *Cell Metabolism*, **2022**,	24.6	9
499	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.. *Movement Disorders*, **2022**,	7	1
498	Disruption of Hfe leads to skeletal muscle iron loading and reduction of hemoproteins involved in oxidative metabolism in a mouse model of hereditary hemochromatosis.. *Biochimica Et Biophysica Acta - General Subjects*, **2022**, 1866, 130082	4	0
497	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum.. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2022**, 14, e12307	5.2	2
496	Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 59	21	3
495	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. *Biomedicines*, **2022**, 10, 1045	4.8	1
494	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. *Nature Communications*, **2022**, 13,	17.4	5
493	Connecting copper and cancer: from transition metal signalling to metalloplasia. *Nature Reviews Cancer*, **2021**,	31.3	48
492	Ferroptosis and NRF2: an emerging battlefield in the neurodegeneration of Alzheimer's disease. *Essays in Biochemistry*, **2021**,	7.6	5
491	Iron accumulation in skeletal muscles of old mice is associated with impaired regeneration after ischaemia-reperfusion damage. *Journal of Cachexia, Sarcopenia and Muscle*, **2021**, 12, 476-492	10.3	6
490	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. *Journal of Alzheimer's Disease Reports*, **2021**, 5, 443-468	3.3	15
489	Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier. *Advanced Science*, **2021**, 8, e2101090	13.6	16
488	Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle. *Nature Communications*, **2021**, 12, 3296	17.4	6
487	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age. *Progress in Neurobiology*, **2021**, 198, 101904	10.9	8

486	amyloid: The known unknowns. *Ageing Research Reviews*, **2021**, 65, 101212	12	13
485	The essential elements of Alzheimer's disease. *Journal of Biological Chemistry*, **2021**, 296, 100105	5.4	42
484	Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease. *Neurotherapeutics*, **2021**, 18, 252-264	6.4	12
483	Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials. *European Journal of Neurology*, **2021**, 28, e1	6	6
482	An integrated mass spectrometry imaging and digital pathology workflow for objective detection of colorectal tumours by unique atomic signatures. *Chemical Science*, **2021**, 12, 10321-10333	9.4	5
481	Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases. *Frontiers in Neuroscience*, **2021**, 15, 618435	5.1	14
480	The acute phase protein lactoferrin is a key feature of Alzheimer's disease and predictor of A burden through induction of APP amyloidogenic processing. *Molecular Psychiatry*, **2021**,	15.1	7
479	From mouse to mouse-ear cress: Nanomaterials as vehicles in plant biotechnology. *Exploration*, **2021**, 1, 9-20		13
478	An Online, Person-Centered, Risk Factor Management Program to Prevent Cognitive Decline: Protocol for A Prospective Behavior-Modification Blinded Endpoint Randomized Controlled Trial. *Journal of Alzheimer's Disease*, **2021**, 83, 1603-1622	4.3	3
477	Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease. *Journal of Neurochemistry*, **2021**, 159, 804-825	6	16
476	Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia-Reperfusion Injury. *Neurotherapeutics*, **2021**, 1	6.4	7
475	Copper and lipid metabolism: A reciprocal relationship. *Biochimica Et Biophysica Acta - General Subjects*, **2021**, 1865, 129979	4	3
474	Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. *Neurobiology of Disease*, **2021**, 159, 105509	7.5	1
473	Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance. *Alzheimer's and Dementia*, **2021**, 17, 1244-1256	1.2	17
472	Deferiprone to delay dementia (the 3D trial). *Alzheimer's and Dementia*, **2020**, 16, e044107	1.2	3
471	Limited cerebral microbleeds effect on regional magnetic susceptibility measured by MRI. *Alzheimer's and Dementia*, **2020**, 16, e044125	1.2	
470	Restricted Effect of Cerebral Microbleeds on Regional Magnetic Susceptibility. *Journal of Alzheimer's Disease*, **2020**, 76, 571-577	4.3	4
469	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 76, 303-315	4.3	7

468	Adrenergic receptor activation reduces amyloid mediated intracellular Zn toxicity in dentate granule cells followed by rescuing impairment of dentate gyrus LTP. *NeuroToxicology*, **2020**, 79, 177-183	4.4	3
467	Alzheimer risk factors age and female sex induce cortical A aggregation by raising extracellular zinc. *Molecular Psychiatry*, **2020**, 25, 2728-2741	15.1	7
466	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12005	5.2	17
465	Iron chelation by deferiprone does not rescue the Niemann-Pick Disease Type C1 mouse model. *BioMetals*, **2020**, 33, 87-95	3.4	2
464	The ubiquitin proteasome system and schizophrenia. *Lancet Psychiatry,the*, **2020**, 7, 528-537	23.3	19
463	Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying amyloid pathology. *Neurobiology of Disease*, **2020**, 139, 104810	7.5	20
462	Zinc Transporter-3 Knockout Mice Demonstrate Age-Dependent Alterations in the Metalloproteome. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
461	Changes in ferrous iron and glutathione promote ferroptosis and frailty in aging. *ELife*, **2020**, 9,	8.9	28
460	Amyloidogenic processing of Alzheimer's disease amyloid precursor protein induces cellular iron retention. *Molecular Psychiatry*, **2020**, 25, 1958-1966	15.1	28
459	Cu (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. *British Journal of Pharmacology*, **2020**, 177, 656-667	8.6	37
458	Preferential Neurodegeneration in the Dentate Gyrus by Amyloid Induced Intracellular ZnDysregulation and Its Defense Strategy. *Molecular Neurobiology*, **2020**, 57, 1875-1888	6.2	7
457	Regional iron distribution and soluble ferroprotein profiles in the healthy human brain. *Progress in Neurobiology*, **2020**, 186, 101744	10.9	8
456	Fibrillar synuclein toxicity depends on functional lysosomes. *Journal of Biological Chemistry*, **2020**, 295, 17497-17513	5.4	14
455	Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy. *Science Advances*, **2020**, 6,	14.3	45
454	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. *BMJ Open*, **2020**, 10, e040100	3	3
453	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. *Nature Communications*, **2020**, 11, 5698	17.4	23
452	The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy. *Journal of Alzheimer's Disease*, **2020**, 77, 753-771	4.3	14
451	Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism. *Scientific Reports*, **2020**, 10, 17631	4.9	3

450	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. *Journal of Alzheimer's Disease*, **2020**, 77, 733-744	4.3	3
449	Parkinsonism as a Third Wave of the COVID-19 Pandemic?. *Journal of Parkinson's Disease*, **2020**, 10, 1343-1353	5.3	27
448	S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau. *Journal of Alzheimer's Disease*, **2020**, 77, 1705-1715	4.3	3
447	Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. *Molecular Psychiatry*, **2020**, 25, 2932-2941	15.1	89
446	Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease. *Neurotherapeutics*, **2020**, 17, 243-251	6.4	7
445	Amyloid Precursor Protein Mediates Neuronal Protection from Rotenone Toxicity. *Molecular Neurobiology*, **2019**, 56, 5471-5482	6.2	8
444	Difference in ability for extracellular Zn influx between human and rat amyloid β and its significance. *NeuroToxicology*, **2019**, 72, 1-5	4.4	5
443	l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease. *Journal of Neurochemistry*, **2019**, 150, 88-106	6	13
442	Decreasing iron neurotoxicity in pantothenate kinase-associated neurodegeneration. *Lancet Neurology, The*, **2019**, 18, 616-617	24.1	2
441	Extracellular Zn-independently attenuated LTP by human amyloid β and rat amyloid β *Biochemical and Biophysical Research Communications*, **2019**, 514, 888-892	3.4	7
440	In vivo synaptic activity-independent co-uptakes of amyloid β and Zn into dentate granule cells in the normal brain. *Scientific Reports*, **2019**, 9, 6498	4.9	9
439	Mice overexpressing hepcidin suggest ferroportin does not play a major role in Mn homeostasis. *Metallomics*, **2019**, 11, 959-967	4.5	4
438	Blood and brain protein levels of ubiquitin-conjugating enzyme E2K (UBE2K) are elevated in individuals with schizophrenia. *Journal of Psychiatric Research*, **2019**, 113, 51-57	5.2	8
437	The Effects of Clioquinol on P-glycoprotein Expression and Biometal Distribution in the Mouse Brain Microvasculature. *Journal of Pharmaceutical Sciences*, **2019**, 108, 2247-2255	3.9	1
436	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. *Science Advances*, **2019**, 5, eaau7220	14.3	44
435	Zn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?. *Nutrients* , **2019**, 11,	6.7	1
434	Cellular Senescence and Iron Dyshomeostasis in Alzheimer's Disease. *Pharmaceuticals*, **2019**, 12,	5.2	34
433	Redox active metals in neurodegenerative diseases. *Journal of Biological Inorganic Chemistry*, **2019**, 24, 1141-1157	3.7	31

432	Zinc in Neurodegeneration **2019**, 201-228		
431	Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia. *Scientific Reports*, **2019**, 9, 2307	4.9	14
430	Axonal dispatch of iron in neuronal signaling. *Nature Chemical Biology*, **2019**, 15, 1135-1136	11.7	3
429	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. *Neurotherapeutics* , **2019**, 16, 192-202	6.4	34
428	Redox Modulating Factors Affect Longevity Regulation in Rotifers. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2019**, 74, 811-814	6.4	5
427	Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying □amyloid pathology. *Neurobiology of Disease*, **2019**, 124, 335-339	7.5	25
426	Molecular Mechanisms of Glutaredoxin Enzymes: Versatile Hubs for Thiol-Disulfide Exchange between Protein Thiols and Glutathione. *Journal of Molecular Biology*, **2019**, 431, 158-177	6.5	33
425	Amyloid □nduced Rapid Zn Influx into Dentate Granule Cells Attenuates Maintained LTP Followed by Retrograde Amnesia. *Molecular Neurobiology*, **2019**, 56, 5041-5050	6.2	3
424	Treating Alzheimer's disease by targeting iron. *British Journal of Pharmacology*, **2019**, 176, 3622-3635	8.6	37
423	Parkinson's disease prevalence and the association with rurality and agricultural determinants. *Parkinsonism and Related Disorders*, **2019**, 61, 198-202	3.6	5
422	Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. *Free Radical Biology and Medicine*, **2019**, 133, 221-233	7.8	177
421	Novel Defense by Metallothionein Induction Against Cognitive Decline: From Amyloid □nduced Excess Zn to Functional Zn Deficiency. *Molecular Neurobiology*, **2018**, 55, 7775-7788	6.2	17
420	Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells. *Pharmaceutical Research*, **2018**, 35, 83	4.5	12
419	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer□ disease. *Personalized Medicine in Psychiatry*, **2018**, 7-8, 14-20	1.1	8
418	Iron as a therapeutic target for Parkinson's disease. *Movement Disorders*, **2018**, 33, 568-574	7	65
417	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE □4-positive cognitively normal adults with high A□amyloid burden. *Scientific Reports*, **2018**, 8, 2034	4.9	21
416	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. *Journal of Alzheimer's Disease*, **2018**, 62, 965-992	4.3	57
415	Metals and Alzheimer's Disease: How Far Have We Come in the Clinic?. *Journal of Alzheimer's Disease*, **2018**, 62, 1369-1379	4.3	92

414	Elevated plasma ferritin in elderly individuals with high neocortical amyloid-load. *Molecular Psychiatry*, **2018**, 23, 1807-1812	15.1	41
413	Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 456-460	5.5	46
412	Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. *Redox Biology*, **2018**, 14, 100-115	11.3	133
411	Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease. *Acta Neuropathologica Communications*, **2018**, 6, 57	7.3	7
410	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. *Acta Neuropsychiatrica*, **2018**, 30, 334-341	3.9	11
409	Adrenergic receptor activation in the basolateral amygdala, which is intracellular Zn-dependent, rescues amyloid induced attenuation of dentate gyrus LTP. *Neurochemistry International*, **2018**, 120, 43-48	4.4	3
408	Targeting metals rescues the phenotype in an animal model of tauopathy. *Metallomics*, **2018**, 10, 1339-1347	4.5	13
407	Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice. *Neurotherapeutics*, **2018**, 15, 1055-1062	6.4	33
406	Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1. *Stem Cell Research*, **2018**, 31, 227-230	1.6	7
405	Iron and Alzheimer's Disease: An Update on Emerging Mechanisms. *Journal of Alzheimer's Disease*, **2018**, 64, S379-S395	4.3	127
404	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. *Journal of Alzheimer's Disease*, **2018**, 61, 169-183	4.3	16
403	What can predict and prevent the long-term use of benzodiazepines?. *Journal of Psychiatric Research*, **2018**, 97, 94-100	5.2	13
402	Glutaredoxins employ parallel monothiol-dithiol mechanisms to catalyze thiol-disulfide exchanges with protein disulfides. *Chemical Science*, **2018**, 9, 1173-1183	9.4	20
401	Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. *Advanced Materials*, **2018**, 30, e1801362	24	226
400	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. *Lecture Notes in Computer Science*, **2018**, 65-72	0.9	1
399	Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein and H-Ferritin. *Journal of Neurochemistry*, **2018**, 147, 831-848	6	44
398	Association of metals with the risk and clinical characteristics of Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 55, 117-121	3.6	10
397	Cognitive effects of adjunctive N-acetyl cysteine in psychosis. *Psychological Medicine*, **2017**, 47, 866-876	6.9	65

396	Ferroptosis and cell death mechanisms in Parkinson's disease. *Neurochemistry International*, **2017**, 104, 34-48	4.4	165
395	Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau. *Journal of Alzheimer's Disease*, **2017**, 56, 849-860	4.3	13
394	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). *Journal of Alzheimer's Disease*, **2017**, 57, 183-193	4.3	38
393	Whole-brain metallomic analysis of the common marmoset (Callithrix jacchus). *Metallomics*, **2017**, 9, 411-423	4.3	8
392	The APOE ε4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer's Disease. *ACS Chemical Neuroscience*, **2017**, 8, 1459-1464	5.7	35
391	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 60-72	5.2	17
390	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. *Analytical Chemistry*, **2017**, 89, 6136-6145	7.8	53
389	Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-ε4 Carriers. *JAMA Neurology*, **2017**, 74, 122-125	17.2	43
388	Tat-haFGF Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1/XBP1 Pathway. *Molecular Therapy - Nucleic Acids*, **2017**, 7, 439-452	10.7	19
387	Novel in vivo experimental viability assays with high sensitivity and throughput capacity using a bdelloid rotifer. *Ecotoxicology and Environmental Safety*, **2017**, 144, 115-122	7	10
386	Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. *Journal of Magnetic Resonance Imaging*, **2017**, 46, 951-971	5.6	128
385	Oxidation of Iron under Physiologically Relevant Conditions in Biological Fluids from Healthy and Alzheimer's Disease Subjects. *ACS Chemical Neuroscience*, **2017**, 8, 731-736	5.7	2
384	The Copper bis(thiosemicarbazone) Complex Cu(atsm) Is Protective Against Cerebral Ischemia Through Modulation of the Inflammatory Milieu. *Neurotherapeutics*, **2017**, 14, 519-532	6.4	28
383	Amyloid Precursor Protein Haploinsufficiency Preferentially Mediates Brain Iron Accumulation in Mice Transgenic for The Huntington's Disease Mutation. *Journal of Huntington's Disease*, **2017**, 6, 115-125	1.9	2
382	Reduction potentials of protein disulfides and catalysis of glutathionylation and deglutathionylation by glutaredoxin enzymes. *Biochemical Journal*, **2017**, 474, 3799-3815	3.8	13
381	Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell*, **2017**, 171, 273-285	56.2	1985
380	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort. *Scientific Reports*, **2017**, 7, 14057	4.9	15
379	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 59, 85-99	4.3	7

378	Nanoscale Imaging Reveals Big Role for Iron in Alzheimer's Disease. *Cell Chemical Biology*, **2017**, 24, 1192-1194	8.1	10
377	Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. *Molecular Psychiatry*, **2017**, 22, 1520-1530	15.1	239
376	Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. *Epilepsia*, **2017**, 58, e136-e141	6.4	21
375	Imaging Metals in Brain Tissue by Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS). *Journal of Visualized Experiments*, **2017**,	1.6	14
374	[P1169]: LACTOFERRIN IS AN IRON TRANSPORTER AND KEY INNATE IMMUNE RESPONSE PROTEIN THAT DIRECTLY BINDS AMYLOID-PRECURSOR PROTEIN TO PROMOTE AMYLOIDOGENIC PROCESSING **2017**, 13, P308-P308		
373	**2017**,		1
372	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. *Acta Neuropathologica Communications*, **2017**, 5, 53	7.3	57
371	Extracellular Zn Is Essential for Amyloid -Induced Cognitive Decline in the Normal Brain and Its Rescue. *Journal of Neuroscience*, **2017**, 37, 7253-7262	6.6	37
370	Glutathione peroxidase 4: a new player in neurodegeneration?. *Molecular Psychiatry*, **2017**, 22, 328-335	15.1	114
369	Lithium suppression of tau induces brain iron accumulation and neurodegeneration. *Molecular Psychiatry*, **2017**, 22, 396-406	15.1	46
368	[P3153]: THE INFLUENCE OF AMYLOID-B PRECURSOR PROTEIN PROTEOLYTIC PROCESSING ON NEURONAL IRON HOMEOSTASIS **2017**, 13, P993-P993		
367	[P3243]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY **2017**, 13, P1033-P1033		
366	[P1244]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN A ELDERLY CONTROLS AND ALZHEIMER's DISEASE PATIENTS **2017**, 13, P454-P455		1
365	Cerebral quantitative susceptibility mapping predicts amyloid-related cognitive decline. *Brain*, **2017**, 140, 2112-2119	11.2	144
364	The Role of Selenium in Neurodegenerative Diseases **2017**, 35-49		1
363	Metalloregulation of Protein Clearance: New Therapeutic Avenues for Neurodegenerative Diseases **2017**, 363-376		
362	Targeting Transition Metals for Neuroprotection in Alzheimer Disease **2017**, 193-215		2
361	S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. *Journal of Clinical Investigation*, **2017**, 127, 4365-4378	15.9	36

360	Amyloid attenuates metabotropic zinc sensing receptor, mZnR/GPR39, dependent Ca , ERK1/2 and Clusterin signaling in neurons. *Journal of Neurochemistry*, **2016**, 139, 221-233	6	20
359	Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. *Neurology*, **2016**, 87, 1093-101	6.5	23
358	Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3 Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease. *Neurodegenerative Diseases*, **2016**, 16, 357-69	2.3	14
357	Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. *NPJ Schizophrenia*, **2016**, 2, 16002	5.5	29
356	XANES: In vivo imaging of metal-protein coordination environments. *Scientific Reports*, **2016**, 6, 20350	4.9	31
355	Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid. *Acta Neuropathologica Communications*, **2016**, 4, 119	7.3	32
354	Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex. *NeuroImage*, **2016**, 137, 124-131	7.9	44
353	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 3, 18-26	5.2	24
352	Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status. *Neurotherapeutics*, **2016**, 13, 614-22	6.4	13
351	Amyloid-Peptide A pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. *Journal of Biological Chemistry*, **2016**, 291, 6134-45	5.4	63
350	A Mixed Methods Approach to Identify Cognitive Warning Signs for Suicide Attempts. *Archives of Suicide Research*, **2016**, 20, 528-38	2.3	7
349	High-resolution complementary chemical imaging of bio-elements in Caenorhabditis elegans. *Metallomics*, **2016**, 8, 156-60	4.5	20
348	Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. *Metallomics*, **2016**, 8, 628-32	4.5	22
347	Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse. *ACS Chemical Neuroscience*, **2016**, 7, 360-6	5.7	24
346	Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice. *ACS Chemical Neuroscience*, **2016**, 7, 119-29	5.7	54
345	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. *Current Alzheimer Research*, **2016**, 13, 787-99	3	17
344	Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases. *Current Topics in Medicinal Chemistry*, **2016**, 16, 3058-3068	3	18
343	Metallo-pathways to Alzheimer's disease: lessons from genetic disorders of copper trafficking. *Metallomics*, **2016**, 8, 831-9	4.5	28

342	Overexpression of Metallothionein-1 Modulates the Phenotype of the Tg2576 Mouse Model of Alzheimer's Disease. *Journal of Alzheimerks Disease*, **2016**, 51, 81-95	4.3	14
341	Iron Regulates Apolipoprotein E Expression and Secretion in Neurons and Astrocytes. *Journal of Alzheimerks Disease*, **2016**, 51, 471-87	4.3	25
340	Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson's substantia nigra. *Signal Transduction and Targeted Therapy*, **2016**, 1, 16015	21	16
339	Delivery of Fluorescent Nanoparticles to the Brain. *Journal of Molecular Neuroscience*, **2016**, 60, 405-409	3.3	13
338	The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update. *Journal of Molecular Neuroscience*, **2016**, 60, 325-335	3.3	41
337	Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 179-197	6	289
336	High order W02-reactive stable oligomers of amyloid- are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid- monomer. *Journal of Alzheimerks Disease*, **2015**, 44, 69-78	4.3	2
335	Parkinson's disease iron deposition caused by nitric oxide-induced loss of amyloid precursor protein. *Journal of Neuroscience*, **2015**, 35, 3591-7	6.6	73
334	Is early-life iron exposure critical in neurodegeneration?. *Nature Reviews Neurology*, **2015**, 11, 536-44	15	70
333	Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way. *Neurobiology of Disease*, **2015**, 81, 38-48	7.5	10
332	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. *Alzheimerks Research and Therapy*, **2015**, 7, 16	9	16
331	A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizure-associated death. *Epilepsia*, **2015**, 56, e73-7	6.4	27
330	Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. *Neurobiology of Disease*, **2015**, 81, 168-75	7.5	59
329	Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease. *ACS Medicinal Chemistry Letters*, **2015**, 6, 1025-9	4.3	31
328	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of Amyloid Toxicity and Are Mediated by Tau. *Neurotherapeutics*, **2015**, 12, 862-73	6.4	35
327	Traumatic brain injury induces elevation of Co in the human brain. *Metallomics*, **2015**, 7, 66-70	4.5	10
326	Biometals and their therapeutic implications in Alzheimer's disease. *Neurotherapeutics*, **2015**, 12, 109-20	6.4	94
325	Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2015**, 57, 69-75	5.5	24

324	Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. *Nature Communications*, **2015**, 6, 6760	17.4	167
323	Selenium, selenoproteins and neurodegenerative diseases. *Metallomics*, **2015**, 7, 1213-28	4.5	155
322	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. *Psychiatry Research*, **2015**, 230, 982-3	9.9	8
321	Direct imaging of ferrous iron dyshomeostasis in ageing. *Chemical Science*, **2015**, 6, 2952-2962	9.4	63
320	Visualising mouse neuroanatomy and function by metal distribution using laser ablation-inductively coupled plasma-mass spectrometry imaging. *Chemical Science*, **2015**, 6, 5383-5393	9.4	59
319	Metal chaperones prevent zinc-mediated cognitive decline. *Neurobiology of Disease*, **2015**, 81, 196-202	7.5	41
318	Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease. *Redox Biology*, **2015**, 4, 363-74	11.3	27
317	Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. *ACS Chemical Neuroscience*, **2015**, 6, 398-402	5.7	57
316	Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells. *Journal of Biological Chemistry*, **2014**, 289, 11007-11019	5.4	34
315	Altered transition metal homeostasis in Niemann-Pick disease, type C1. *Metallomics*, **2014**, 6, 542-53	4.5	18
314	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. *Metallomics*, **2014**, 6, 1216-9	4.5	31
313	Quantitation and localization of intracellular redox active metals by X-ray fluorescence microscopy in cortical neurons derived from APP and APLP2 knockout tissue. *Metallomics*, **2014**, 6, 1894-904	4.5	20
312	The effect of paraformaldehyde fixation and sucrose cryoprotection on metal concentration in murine neurological tissue. *Journal of Analytical Atomic Spectrometry*, **2014**, 29, 565-570	3.7	39
311	An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. *Chemical Science*, **2014**, 5, 2160-2169	9.4	82
310	Biological metals and metal-targeting compounds in major neurodegenerative diseases. *Chemical Society Reviews*, **2014**, 43, 6727-49	58.5	336
309	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. *Neurology*, **2014**, 83, 1345-52	6.5	46
308	A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe(2+) under physiologically relevant conditions. *Biochimica Et Biophysica Acta - General Subjects*, **2014**, 1840, 3299-310	4	19
307	Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. *Neurobiology of Disease*, **2014**, 71, 34-42	7.5	32

306	Response to comment on Moore et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes care 2013;36:2981-2987. *Diabetes Care*, **2014**, 37, e151	14.6	4
305	Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease. *Molecular Neurodegeneration*, **2014**, 9, 27	19	47
304	Motor and cognitive deficits in aged tau knockout mice in two background strains. *Molecular Neurodegeneration*, **2014**, 9, 29	19	91
303	Neuroprotective peptide-macrocycle conjugates reveal complex structure-activity relationships in their interactions with amyloid *Metallomics*, **2014**, 6, 1931-40	4.5	16
302	Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neuroscience*, **2014**, 34, 8021-31	6.6	118
301	An anemia of Alzheimer's disease. *Molecular Psychiatry*, **2014**, 19, 1227-34	15.1	81
300	Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. *Journal of Alzheimer's Disease*, **2014**, 39, 661-8	4.3	57
299	Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35 Suppl 2, S74-8	5.6	190
298	Ceruloplasmin and amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. *Free Radical Biology and Medicine*, **2014**, 69, 331-7	7.8	44
297	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. *Journal of Neuroimmunology*, **2014**, 273, 65-71	3.5	46
296	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. *Alzheimer's and Dementia*, **2014**, 10, 53-61	1.2	84
295	A blood-based predictor for neocortical A burden in Alzheimer's disease: results from the AIBL study. *Molecular Psychiatry*, **2014**, 19, 519-26	15.1	85
294	Plasma amyloid- levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. *Journal of Alzheimer's Disease*, **2014**, 40, 95-104	4.3	34
293	A review of amyloid neuroimaging in Alzheimer's disease. *Frontiers in Neuroscience*, **2014**, 8, 327	5.1	61
292	The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. *Journal of Clinical Psychiatry*, **2014**, 75, 628-36	4.6	125
291	P4-369: REVISITING THE ALZHEIMER'S AND PARKINSONISM PHENOTYPES OF TAU KO MICE: POTENTIAL GENETIC BACKGROUND EFFECT **2014**, 10, P924-P924		
290	Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2014**, 38, 809-22	4.3	78
289	Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. *PLoS ONE*, **2014**, 9, e86498	3.7	57

288	Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology. *Frontiers in Aging Neuroscience*, **2014**, 6, 91	5.3	30
287	amyloid in biological samples: not all A detection methods are created equal. *Frontiers in Aging Neuroscience*, **2014**, 6, 203	5.3	2
286	Copper-uptake is critical for the down regulation of synapsin and dynamin induced by neocuproine: modulation of synaptic activity in hippocampal neurons. *Frontiers in Aging Neuroscience*, **2014**, 6, 319	5.3	12
285	Copper: from neurotransmission to neuroproteostasis. *Frontiers in Aging Neuroscience*, **2014**, 6, 143	5.3	75
284	A novel approach to rapidly prevent age-related cognitive decline. *Aging Cell*, **2014**, 13, 351-9	9.9	40
283	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). *International Psychogeriatrics*, **2014**, 26, 543-54	3.4	30
282	Associations between gonadotropins, testosterone and amyloid in men at risk of Alzheimer's disease. *Molecular Psychiatry*, **2014**, 19, 69-75	15.1	83
281	Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. *PLoS ONE*, **2014**, 9, e114174	3.7	104
280	Amyloid mediated Zn2+ influx into dentate granule cells transiently induces a short-term cognitive deficit. *PLoS ONE*, **2014**, 9, e115923	3.7	30
279	The Clinical Implications of Impaired Zinc Signaling in the Brain **2014**, 183-196		1
278	Metal dyshomeostasis and oxidative stress in Alzheimer's disease. *Neurochemistry International*, **2013**, 62, 540-55	4.4	288
277	Increasing intracellular bioavailable copper selectively targets prostate cancer cells. *ACS Chemical Biology*, **2013**, 8, 1621-31	4.9	89
276	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. *BMC Psychology*, **2013**, 1, 30	2.8	107
275	Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care*, **2013**, 36, 2981-7	14.6	223
274	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. *Metallomics*, **2013**, 5, 1656-62	4.5	35
273	Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. *Journal of Alzheimerks Disease*, **2013**, 34, 171-82	4.3	40
272	Metallostasis in Alzheimer's disease. *Free Radical Biology and Medicine*, **2013**, 62, 76-89	7.8	238
271	Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. *Annals of Neurology*, **2013**, 73, 554-9	9.4	170

270	The metal theory of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S277-81	4.3	174
269	Direct in vivo imaging of essential bioinorganics in Caenorhabditis elegans. *Metallomics*, **2013**, 5, 627-35	4.5	36
268	The effect of dopamine on MPTP-induced rotarod disability. *Neuroscience Letters*, **2013**, 543, 105-9	3.3	22
267	Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. *Molecular Psychiatry*, **2013**, 18, 875-81	15.1	144
266	BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2457-64	5.6	93
265	Decline in cognitive function over 18 months in healthy older adults with high amyloid-β *Journal of Alzheimer's Disease*, **2013**, 34, 861-71	4.3	34
264	Links between copper and cholesterol in Alzheimer's disease. *Frontiers in Physiology*, **2013**, 4, 111	4.6	29
263	Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). *Archives of Clinical Neuropsychology*, **2013**, 28, 320-30	2.7	70
262	Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β prodromal Alzheimer's disease?. *Journal of Alzheimer's Disease*, **2013**, 33, 1167-76	4.3	30
261	A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. *Australian and New Zealand Journal of Psychiatry*, **2013**, 47, 564-8	2.6	44
260	Amine oxidase activity of β amyloid precursor protein modulates systemic and local catecholamine levels. *Molecular Psychiatry*, **2013**, 18, 245-54	15.1	12
259	Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. *Neuropsychology*, **2013**, 27, 322-332	3.8	30
258	Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013;36:2981-2987. *Diabetes Care*, **2013**, 36, 3850-3850	14.6	2
257	Rapid decline in episodic memory in healthy older adults with high amyloid-β *Journal of Alzheimer's Disease*, **2013**, 33, 675-9	4.3	42
256	Iron accumulates in Huntington's disease neurons: protection by deferoxamine. *PLoS ONE*, **2013**, 8, e77023	3.7	88
255	Deserves a hearing? A case report of remitting tinnitus with N-acetyl cysteine. *African Journal of Psychiatry*, **2013**, 16, 238, 240		
254	A delicate balance: Iron metabolism and diseases of the brain. *Frontiers in Aging Neuroscience*, **2013**, 5, 34	5.3	235
253	Copper status in Alzheimer's disease and other neurodegenerative disorders 2013. *International Journal of Alzheimer's Disease*, **2013**, 2013, 838274	3.7	4

252	Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction. *International Journal of Alzheimer's Disease*, **2013**, 2013, 623241	3.7	29
251	Presenilin promotes dietary copper uptake. *PLoS ONE*, **2013**, 8, e62811	3.7	21
250	Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica. *PLoS ONE*, **2013**, 8, e72543	3.7	15
249	The Role of the Plasma Membrane Redox System in the Pathogenesis of Alzheimer's Disease. *Oxidative Stress in Applied Basic Research and Clinical Practice*, **2013**, 55-69		
248	Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues. *Clinical Science*, **2012**, 122, 409-19	6.5	6
247	Blood-based protein biomarkers for diagnosis of Alzheimer disease. *Archives of Neurology*, **2012**, 69, 1318-25		271
246	Effects of N-acetyl cysteine on cognitive function in bipolar disorder. *Psychiatry and Clinical Neurosciences*, **2012**, 66, 514-7	6.2	40
245	"The Sound of Fear": assessing vocal fundamental frequency as a physiological indicator of social anxiety disorder. *Journal of Anxiety Disorders*, **2012**, 26, 811-22	10.9	23
244	Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2012**, 37, 132-5	5.5	21
243	The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. *Journal of Experimental Medicine*, **2012**, 209, 837-54	16.6	113
242	Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. *BMC Medicine*, **2012**, 10, 91	11.4	72
241	Translating the Rosetta Stone of N-acetylcysteine. *Biological Psychiatry*, **2012**, 71, 935-6	7.9	15
240	Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. *Nature Medicine*, **2012**, 18, 291-5	50.5	385
239	Characterization of the role of the antioxidant proteins metallothioneins 1 and 2 in an animal model of Alzheimer's disease. *Cellular and Molecular Life Sciences*, **2012**, 69, 3665-81	10.3	24
238	Characterization of the role of metallothionein-3 in an animal model of Alzheimer's disease. *Cellular and Molecular Life Sciences*, **2012**, 69, 3683-700	10.3	35
237	Utility of an improved model of amyloid-beta (Aβ) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. *Molecular Neurodegeneration*, **2012**, 7, 57	19	127
236	Metal chaperones: a holistic approach to the treatment of Alzheimer's disease. *Frontiers in Psychiatry*, **2012**, 3, 15	5	18
235	The role of metallobiology and amyloid-β peptides in Alzheimer's disease. *Journal of Neurochemistry*, **2012**, 120 Suppl 1, 149-166	6	198

234	Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. *Free Radical Biology and Medicine*, **2012**, 52, 298-302	7.8	120
233	Alterations in brain transition metals in Huntington disease: an evolving and intricate story. *Archives of Neurology*, **2012**, 69, 887-93		104
232	P2X7 receptor-mediated scavenger activity of mononuclear phagocytes toward non-opsonized particles and apoptotic cells is inhibited by serum glycoproteins but remains active in cerebrospinal fluid. *Journal of Biological Chemistry*, **2012**, 287, 17318-17330	5.4	18
231	Caenorhabditis elegans maintains highly compartmentalized cellular distribution of metals and steep concentration gradients of manganese. *PLoS ONE*, **2012**, 7, e32685	3.7	41
230	PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease. *Journal of Huntingtonks Disease*, **2012**, 1, 211-9	1.9	46
229	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. *International Psychogeriatrics*, **2012**, 24, 197-204	3.4	31
228	Rapid generation of dityrosine cross-linked A□oligomers via Cu-redox cycling. *Methods in Molecular Biology*, **2012**, 849, 3-10	1.4	6
227	Copper and Alzheimer Disease: The Good, the Bad and the Ugly **2012**, 609-645		
226	The neurophysiology and pathology of brain zinc. *Journal of Neuroscience*, **2011**, 31, 16076-85	6.6	241
225	Chapter 8:Biological Metals: Metallostasis and Alzheimer's Disease. *RSC Drug Discovery Series*, **2011**, 152-173		
224	N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. *Neuroscience Letters*, **2011**, 499, 149-53	3.3	66
223	The plasma membrane redox system in Alzheimer's disease. *Experimental Neurology*, **2011**, 228, 9-14	5.7	7
222	Copper modulation as a therapy for Alzheimer's disease?. *International Journal of Alzheimerks Disease*, **2011**, 2011, 370345	3.7	8
221	N-acetylcysteine for major depressive episodes in bipolar disorder. *Revista Brasileira De Psiquiatria*, **2011**, 33, 374-8	2.6	85
220	GSK-3 in Neurodegenerative Diseases. *International Journal of Alzheimerks Disease*, **2011**, 2011, 189246	3.7	96
219	A Copper Binding Site within the Pathological Conformer Epitope of Mutant SOD1. *Frontiers in Neuroscience*, **2011**, 5, 97	5.1	2
218	Disturbed copper bioavailability in Alzheimer's disease. *International Journal of Alzheimerks Disease*, **2011**, 2011, 345614	3.7	23
217	Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. *PLoS ONE*, **2011**, 6, e17669	3.7	97

216	The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. *Journal of Neurochemistry*, **2011**, 119, 220-30	6	142
215	Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder. *Acta Neuropsychiatrica*, **2011**, 23, 87-88	3.9	7
214	N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. *Journal of Affective Disorders*, **2011**, 129, 317-20	6.6	82
213	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. *Journal of Affective Disorders*, **2011**, 135, 389-94	6.6	139
212	Who's left? Symptoms of schizophrenia that predict clinical trial dropout. *Human Psychopharmacology*, **2011**, 26, 609-13	2.3	6
211	Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. *Journal of Alzheimer's Disease*, **2011**, 27, 909-22	4.3	67
210	Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. *Neurology*, **2011**, 76, 1091-8	8.5	121
209	Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.. *Journal of Biological Chemistry*, **2011**, 286, 27068	5.4	78
208	Presenilins promote the cellular uptake of copper and zinc and maintain copper chaperone of SOD1-dependent copper/zinc superoxide dismutase activity. *Journal of Biological Chemistry*, **2011**, 286, 9776-86	5.4	64
207	Copper promotes the trafficking of the amyloid precursor protein. *Journal of Biological Chemistry*, **2011**, 286, 8252-8262	5.4	79
206	Role of amyloid-β metal interactions in Alzheimer's disease. *Future Neurology*, **2011**, 6, 641-659	1.5	16
205	Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. *Dementia and Geriatric Cognitive Disorders*, **2011**, 31, 173-8	2.6	85
204	Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. *Journal of Biological Chemistry*, **2011**, 286, 18320-30	5.4	43
203	Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. *Journal of Clinical Psychiatry*, **2011**, 72, 909-13	4.6	25
202	Altered microglial copper homeostasis in a mouse model of Alzheimer's disease. *Journal of Neurochemistry*, **2010**, 114, 1630-8	6	63
201	Three-dimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine lesioned mouse brain. *Metallomics*, **2010**, 2, 745-53	4.5	65
200	Tau protein: relevance to Parkinson's disease. *International Journal of Biochemistry and Cell Biology*, **2010**, 42, 1775-8	5.6	140
199	Behavioural phenotype of APPC100.V717F transgenic mice over-expressing a mutant Abeta-bearing fragment is associated with reduced NMDA receptor density. *Behavioural Brain Research*, **2010**, 209, 27-35	3.4	11

198	Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. *Cell*, **2010**, 142, 857-67	56.2	483
197	Insulin-like signaling determines survival during stress via posttranscriptional mechanisms in C. elegans. *Cell Metabolism*, **2010**, 12, 260-72	24.6	76
196	Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. *Progress in Neurobiology*, **2010**, 92, 1-18	10.9	227
195	Kalzium ist nicht alles. *Neuron*, **2010**, 65, 143-4	13.9	5
194	Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?. *Journal of Neuroscience*, **2010**, 30, 1631-6	6.6	285
193	Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. *Journal of Alzheimerks Disease*, **2010**, 20, 1233-42	4.3	111
192	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. *Journal of Alzheimerks Disease*, **2010**, 20, 509-16	4.3	306
191	Copper in the brain and Alzheimer's disease. *Journal of Biological Inorganic Chemistry*, **2010**, 15, 61-76	3.7	330
190	Generation of soluble oligomeric beta-amyloid species via copper catalyzed oxidation with implications for Alzheimer's disease: a DFT study. *Journal of Molecular Modeling*, **2010**, 16, 1103-8	2	5
189	Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. *BioMetals*, **2010**, 23, 173-9	3.4	101
188	Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. *BioMetals*, **2010**, 23, 1085-95	3.4	20
187	Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. *Pharmacology Biochemistry and Behavior*, **2010**, 97, 293-300	3.9	13
186	Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. *European Journal of Pharmacology*, **2010**, 649, 224-8	5.3	44
185	Monomerized Cu, Zn-superoxide dismutase induces oxidative stress through aberrant Cu binding. *Free Radical Biology and Medicine*, **2010**, 48, 945-52	7.8	9
184	Role of Metals in Alzheimer Disease **2010**, 543-558		1
183	A domain level interaction network of amyloid precursor protein and Abeta of Alzheimer's disease. *Proteomics*, **2010**, 10, 2377-95	4.8	38
182	Syntaxin 5 is required for copper homeostasis in Drosophila and mammals. *PLoS ONE*, **2010**, 5, e14303	3.7	15
181	Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. *Journal of Biological Chemistry*, **2009**, 284, 21899-21907	5.4	48

180	Copper transport into the secretory pathway is regulated by oxygen in macrophages. *Journal of Cell Science*, **2009**, 122, 1315-21	5.3	77
179	Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 381-6	11.5	227
178	The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. *Journal of Biological Chemistry*, **2009**, 284, 22697-702	5.4	94
177	Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice. *Cellular and Molecular Neurobiology*, **2009**, 29, 757-67	4.6	14
176	Enzyme solid-state support assays: a surface plasmon resonance and mass spectrometry coupled study of immobilized insulin degrading enzyme. *European Biophysics Journal*, **2009**, 38, 407-14	1.9	29
175	Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. *Molecular Neurodegeneration*, **2009**, 4, 2	19	31
174	Zinc in the physiology and pathology of the CNS. *Nature Reviews Neuroscience*, **2009**, 10, 780-91	13.5	537
173	Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial. *Acta Neuropsychiatrica*, **2009**, 21, 285-91	3.9	11
172	Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. *Acta Neuropsychiatrica*, **2009**, 21, 239-45	3.9	5
171	Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. *Behavioural Brain Research*, **2009**, 198, 258-62	3.4	59
170	Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. *Neurobiology of Aging*, **2009**, 30, 1069-77	5.6	110
169	Quantitative elemental bio-imaging of Mn, Fe, Cu and Zn in 6-hydroxydopamine induced Parkinsonism mouse models. *Metallomics*, **2009**, 1, 53-58	4.5	113
168	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. *International Psychogeriatrics*, **2009**, 21, 672-87	3.4	506
167	Targeting the progression of Parkinson's disease. *Current Neuropharmacology*, **2009**, 7, 9-36	7.6	54
166	A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. *Current Medicinal Chemistry*, **2009**, 16, 2965-76	4.3	76
165	Pharmacotherapeutic targets in Alzheimer's disease. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 61-86	5.6	44
164	SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress. *PLoS ONE*, **2009**, 4, e5684	3.7	68
163	Clioquinol Protects Against Cell Death in Parkinson□ Disease Models In Vivo and In Vitro. *Advances in Behavioral Biology*, **2009**, 431-442		6

162	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurology, The*, **2008**, 7, 779-86	24.1	577
161	Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. *International Journal of Neuropsychopharmacology*, **2008**, 11, 851-76	5.8	669
160	N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. *Biological Psychiatry*, **2008**, 64, 361-8	7.9	415
159	N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. *Biological Psychiatry*, **2008**, 64, 468-75	7.9	401
158	Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. *Neuron*, **2008**, 59, 43-55	13.9	565
157	Glutathione: a novel treatment target in psychiatry. *Trends in Pharmacological Sciences*, **2008**, 29, 346-51	13.2	152
156	Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 181-98	5.6	198
155	Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. *Biochemical Society Transactions*, **2008**, 36, 1282-7	5.1	100
154	Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. *Neuropsychopharmacology*, **2008**, 33, 2187-99	8.7	284
153	Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms. *Biochemical Journal*, **2008**, 412, 141-52	3.8	69
152	Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 6813-8	11.5	160
151	Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. *Journal of Biological Chemistry*, **2008**, 283, 31657-64	5.4	96
150	Insights into Zn2+ homeostasis in neurons from experimental and modeling studies. *American Journal of Physiology - Cell Physiology*, **2008**, 294, C726-42	5.4	153
149	Drug development based on the metals hypothesis of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2008**, 15, 223-40	4.3	224
148	Therapeutics for Alzheimer's disease based on the metal hypothesis. *Neurotherapeutics*, **2008**, 5, 421-32	6.4	437
147	Twenty years of metallo-neurobiology: where to now?. *European Biophysics Journal*, **2008**, 37, 241-5	1.9	49
146	Investigating copper-regulated protein expression in Menkes fibroblasts using antibody microarrays. *Proteomics*, **2008**, 8, 1819-31	4.8	8
145	Sensitive, selective, and irreversible inhibition of cyclooxygenase-2 activity by copper. *ChemMedChem*, **2008**, 3, 223-5	3.7	1

144	Metals in Alzheimer's and Parkinson's diseases. *Current Opinion in Chemical Biology*, **2008**, 12, 222-8	9.7	573
143	Metal Complexing Agents for the Treatment of Alzheimer's Disease **2007**, 107-136		2
142	Mitochondrial oxidative stress causes hyperphosphorylation of tau. *PLoS ONE*, **2007**, 2, e536	3.7	237
141	The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. *FEBS Journal*, **2007**, 274, 3775-83	5.7	56
140	Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. *Free Radical Biology and Medicine*, **2007**, 42, 1534-42	7.8	36
139	Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. *Neuroscience*, **2007**, 150, 357-69	3.9	96
138	Metal Ions and Alzheimer's Disease **2007**, 333-361		
137	Mitochondria in aging and Alzheimer's disease. *Rejuvenation Research*, **2007**, 10, 349-57	2.6	45
136	Mechanisms of copper ion mediated Huntington's disease progression. *PLoS ONE*, **2007**, 2, e334	3.7	142
135	A Structure and Aggregation **2007**, 113-131		0
134	Free Radicals, Metal Ions, and A Aggregation and Neurotoxicity **2007**, 31-47		3
133	Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. *Journal of Inorganic Biochemistry*, **2006**, 100, 952-62	4.2	85
132	RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. *Current Alzheimer Research*, **2006**, 3, 221-7	3	42
131	Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. *Journal of Biological Chemistry*, **2006**, 281, 17670-80	5.4	222
130	Metal homeostasis in Alzheimer's disease. *Expert Review of Neurotherapeutics*, **2006**, 6, 711-22	4.3	36
129	Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. *Journal of Biological Chemistry*, **2006**, 281, 15145-54	5.4	150
128	Elevated cortical zinc in Alzheimer disease. *Neurology*, **2006**, 67, 69-75	6.5	202
127	Neurodegenerative Diseases and Metal Ions. A Concluding Overview **2006**, 427-435		2

126	The Role of Metal Ions in Neurology. An Introduction **2006**, 1-7		5
125	Metals and Alzheimer's disease. *Journal of Alzheimer's Disease*, **2006**, 10, 145-63	4.3	265
124	Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. *Aging Cell*, **2006**, 5, 69-79	9.9	67
123	Therapeutic treatments for Alzheimer's disease based on metal bioavailability. *Drug News and Perspectives*, **2006**, 19, 469-74		35
122	Alzheimer disease □amyloid activity mimics cholesterol oxidase. *Journal of Clinical Investigation*, **2006**, 116, 2828-2828	15.9	78
121	Amyloid-beta metal interaction and metal chelation. *Sub-Cellular Biochemistry*, **2005**, 38, 235-54	5.5	54
120	Model studies of cholesterol and ascorbate oxidation by copper complexes: relevance to Alzheimer's disease beta-amyloid metallochemistry. *Journal of Inorganic Biochemistry*, **2005**, 99, 2403-22	4.2	33
119	Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. *Journal of Biological Chemistry*, **2005**, 280, 41732-43	5.4	235
118	The neurobiology of zinc in health and disease. *Nature Reviews Neuroscience*, **2005**, 6, 449-62	13.5	1390
117	Metals and amyloid-beta in Alzheimer's disease. *International Journal of Experimental Pathology*, **2005**, 86, 147-59	2.8	254
116	Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment. *Free Radical Biology and Medicine*, **2005**, 38, 258-61	7.8	66
115	Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. *Journal of Peptide Science*, **2005**, 11, 353-60	2.1	77
114	Copper and zinc in Alzheimer's disease and amyotrophic lateral sclerosis **2005**, 157-165		
113	Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region. *Current Alzheimer Research*, **2005**, 2, 249-54	3	34
112	Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. *Journal of Biological Chemistry*, **2005**, 280, 13355-63	5.4	101
111	Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. *Journal of Clinical Investigation*, **2005**, 115, 2556-63	15.9	108
110	Methionine Sulfoxide Reductase System. *Oxidative Stress and Disease*, **2005**, 199-212		
109	Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease. *Drug Design Reviews Online*, **2004**, 1, 75-82		9

108	Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. *Journal of Neuroscience*, **2004**, 24, 3453-9	6.6	122
107	The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu2+ neurotoxicity in vivo. *FASEB Journal*, **2004**, 18, 1701-3	0.9	37
106	Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. *Journal of Biological Chemistry*, **2004**, 279, 42528-34	5.4	92
105	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. *FASEB Journal*, **2004**, 18, 1427-9	0.9	231
104	Serum copper: a biomarker for Alzheimer disease?. *Archives of Neurology*, **2004**, 61, 631-2		10
103	Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neuroscience*, **2004**, 24, 7945-50	6.6	46
102	Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. *Journal of Biological Chemistry*, **2004**, 279, 8602-7	5.4	67
101	Neurodegenerative diseases and oxidative stress. *Nature Reviews Drug Discovery*, **2004**, 3, 205-14	64.1	2474
100	Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. *Experimental Gerontology*, **2004**, 39, 1641-9	4.5	118
99	Redox-active metals, oxidative stress, and Alzheimer's disease pathology. *Annals of the New York Academy of Sciences*, **2004**, 1012, 153-63	6.5	329
98	The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. *Annals of the New York Academy of Sciences*, **2004**, 1035, 34-48	6.5	45
97	Iron inhibits neurotoxicity induced by trace copper and biological reductants. *Journal of Biological Inorganic Chemistry*, **2004**, 9, 269-80	3.7	39
96	Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. *Journal of Biological Inorganic Chemistry*, **2004**, 9, 954-60	3.7	195
95	Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloid beta-peptide by NMR. *Journal of Peptide Science*, **2004**, 10, 210-7	2.1	18
94	Metal-protein attenuating compounds and Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2004**, 13, 1585-92	5.9	53
93	Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. *Biochemistry*, **2004**, 43, 560-8	3.2	317
92	Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease. *Journal of Biological Chemistry*, **2004**, 279, 14673-8	5.4	38
91	Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. *Neurobiology of Aging*, **2004**, 25, 563-8	5.6	118

90	Copper in Brain and Neurodegeneration **2004**, 1-21		1
89	Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. *Journal of Biological Chemistry*, **2003**, 278, 42959-65	5.4	156
88	Copper, zinc, and the metallobiology of Alzheimer disease. *Alzheimer Disease and Associated Disorders*, **2003**, 17, 147-50	2.5	88
87	Methionine oxidation: Implications for the mechanism of toxicity of the □amyloid peptide from Alzheimer's disease. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 413-417		13
86	Current status of metals as therapeutic targets in Alzheimer's disease. *Journal of the American Geriatrics Society*, **2003**, 51, 1143-8	5.6	171
85	Methionine oxidation: Implications for the mechanism of toxicity of the □amyloid peptide from Alzheimer's disease. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 413-417	2.1	3
84	Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. *Lancet, The*, **2003**, 361, 1258-65	40	276
83	The metallobiology of Alzheimer's disease. *Trends in Neurosciences*, **2003**, 26, 207-14	13.3	1074
82	Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. *Neuron*, **2003**, 37, 899-909	13.9	535
81	Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. *Journal of Biological Chemistry*, **2003**, 278, 2977-82	5.4	171
80	Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 11193-4	11.5	121
79	Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. *Archives of Neurology*, **2003**, 60, 1685-91		861
78	Importance of Copper and Zinc in Alzheimer's Disease and the Biology of Amyloid-□Protein and Amyloid-□Protein Precursor **2003**, 245-261		
77	Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. *Journal of Molecular Neuroscience*, **2002**, 19, 77-82	3.3	53
76	Is ALS caused by an altered oxidative activity of mutant superoxide dismutase?. *Nature Neuroscience*, **2002**, 5, 919; author reply 919-20	25.5	26
75	The galvanization of beta-amyloid in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 7317-9	11.5	122
74	Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. *Journal of Biological Chemistry*, **2002**, 277, 44670-6	5.4	272
73	Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). *Journal of Biological Chemistry*, **2002**, 277, 40302-8	5.4	472

72	An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. *Journal of Biological Chemistry*, **2002**, 277, 45518-28	5.4	395
71	Metal complexing agents as therapies for Alzheimer's disease. *Neurobiology of Aging*, **2002**, 23, 1031-8	5.6	276
70	Response: nd C is for Clioquinol he A s of Alzheimer's disease. *Trends in Neurosciences*, **2002**, 25, 123-124	13.3	0
69	Copper, Zinc, and Alzheimer Disease **2002**, 229-239		
68	Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: focus on Alzheimer's disease and age-related cataracts. *Novartis Foundation Symposium*, **2001**, 235, 26-38; discussion 38-43		13
67	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits **2001**, 341-361		8
66	Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. *Journal of Neurochemistry*, **2001**, 76, 1509-20	6	183
65	Synaptically released zinc: physiological functions and pathological effects. *BioMetals*, **2001**, 14, 353-66	3.4	286
64	Redox-active iron mediates amyloid-beta toxicity. *Free Radical Biology and Medicine*, **2001**, 30, 447-50	7.8	310
63	Computerised cognitive assessment of concussed Australian Rules footballers. *British Journal of Sports Medicine*, **2001**, 35, 354-60	10.3	109
62	Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. *Biochemistry*, **2001**, 40, 8073-84	3.2	247
61	Clioquinol's return: cautions from Japan. *Science*, **2001**, 292, 2251-2	33.3	29
60	Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. *Neuron*, **2001**, 30, 665-76	13.9	1276
59	Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. *Journal of Biological Chemistry*, **2001**, 276, 20466-73	5.4	530
58	Therapeutic targets in the biology of Alzheimer disease. *Current Opinion in Psychiatry*, **2001**, 14, 341-348	4.9	11
57	Synaptically released zinc: Physiological functions and pathological effects **2001**, 167-180		1
56	Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. *Journal of Neurochemistry*, **2000**, 75, 1219-33	6	479
55	Metal chelation as a potential therapy for Alzheimer's disease. *Annals of the New York Academy of Sciences*, **2000**, 920, 292-304	6.5	138

54	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. *NeuroReport*, **2000**, 11, 2491-3	1.7	121
53	Metals and neuroscience. *Current Opinion in Chemical Biology*, **2000**, 4, 184-91	9.7	633
52	Oxidative processes in Alzheimer's disease: the role of abeta-metal interactions. *Experimental Gerontology*, **2000**, 35, 445-51	4.5	135
51	Alzheimer's disease, beta-amyloid protein and zinc. *Journal of Nutrition*, **2000**, 130, 1488S-92S	4.1	84
50	Could Abeta and AbetaPP be Antioxidants?. *Journal of Alzheimerks Disease*, **2000**, 2, 83-84	4.3	9
49	Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. *Journal of Biological Chemistry*, **2000**, 275, 19439-42	5.4	309
48	Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. *Journal of Structural Biology*, **2000**, 130, 209-16	3.4	76
47	3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. *Biochemistry*, **2000**, 39, 7266-75	3.2	154
46	Copper catalyzed oxidation of Alzheimer Abeta. *Cellular and Molecular Biology*, **2000**, 46, 777-83	1.1	52
45	Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. *Journal of Neurochemistry*, **1999**, 72, 2092-8	6	68
44	Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. *Journal of Neurochemistry*, **1999**, 72, 2479-87	6	60
43	The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. *Journal of Neuroscience*, **1999**, 19, 9170-9	6.6	188
42	Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. *European Journal of Clinical Investigation*, **1999**, 29, 569-70	4.6	18
41	Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. *Brain Research*, **1999**, 842, 439-44	3.7	252
40	Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Annals of Neurology*, **1999**, 46, 860-6	9.4	1572
39	Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. *Journal of Biological Chemistry*, **1999**, 274, 23223-8	5.4	372
38	The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. *Biochemistry*, **1999**, 38, 7609-16	3.2	1016
37	Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. *Journal of Biological Chemistry*, **1999**, 274, 37111-6	5.4	602

36	Zinc and Alzheimer's Disease: An Update. *Nutritional Neuroscience*, **1999**, 2, 191-208	3.6	5
35	Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. *Biochemistry*, **1999**, 38, 4595-603	3.2	117
34	Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. *Metal Ions in Biological Systems*, **1999**, 36, 309-64		60
33	Beta-amyloid augments platelet aggregation: reduced activity of familial angiopathy-associated mutants. *Molecular Psychiatry*, **1998**, 3, 500-7	15.1	11
32	Potential therapeutic targets for Alzheimer disease. *Expert Opinion on Therapeutic Targets*, **1998**, 2, 157-179		5
31	Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. *Journal of Biological Chemistry*, **1998**, 273, 5013-9	5.4	84
30	Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. *European Neurology*, **1998**, 39, 111-8	2.1	71
29	Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. *Journal of Biological Chemistry*, **1998**, 273, 12817-26	5.4	814
28	Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery?. *Archives of Neurology*, **1998**, 55, 1179-80		32
27	Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. *Journal of Biological Chemistry*, **1997**, 272, 26464-70	5.4	253
26	Metallothioneins in brain--the role in physiology and pathology. *Toxicology and Applied Pharmacology*, **1997**, 142, 229-42	4.6	164
25	Cerebral Zinc Metabolism in Alzheimer Disease **1997**, 225-237		2
24	Response. *Science*, **1995**, 268, 1921-3	33.3	62
23	LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. *Cell*, **1995**, 82, 331-40	56.2	459
22	Genetic studies of Alzheimer's disease: lessons learned and future imperatives. *Neurobiology of Aging*, **1994**, 15 Suppl 2, S145-8	5.6	2
21	Rapid induction of Alzheimer A beta amyloid formation by zinc. *Science*, **1994**, 265, 1464-7	33.3	1381
20	Interaction between the zinc (II) and the heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP). *FEBS Letters*, **1994**, 355, 151-4	3.8	75
19	The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. *Journal of Biological Chemistry*, **1994**, 269, 26618-21	5.4	86

18	Modulation of A beta adhesiveness and secretase site cleavage by zinc. *Journal of Biological Chemistry*, **1994**, 269, 12152-8	5.4	216
17	The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily.. *Journal of Biological Chemistry*, **1994**, 269, 26618-26621	5.4	91
16	The Roles of Zinc and Copper in the Function and Metabolism of the Amyloid Protein Precursor Superfamily **1994**, 169-180		
15	The beta A4 amyloid protein precursor in human circulation. *Annals of the New York Academy of Sciences*, **1993**, 695, 175-82	6.5	12
14	The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. *Nature Genetics*, **1993**, 5, 344-50	36.3	1153
13	Genetic heterogeneity of gene defects responsible for familial Alzheimer disease. *Genetica*, **1993**, 91, 255-63	1.5	26
12	A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. *Journal of Biological Chemistry*, **1993**, 268, 16109-12	5.4	206
11	Beta A4 amyloid protein and its precursor in Alzheimer's disease **1992**, 56, 97-117		28
10	Human brain beta A4 amyloid protein precursor of Alzheimer's disease: purification and partial characterization. *Journal of Neurochemistry*, **1992**, 59, 1490-8	6	45
9	Specific binding of the alzheimer A4 amyloid precursor to collagen, laminin, and heparin. *The Protein Journal*, **1992**, 11, 398-399		20
8	An abnormality of plasma amyloid protein precursor in Alzheimer's disease. *Annals of Neurology*, **1992**, 32, 57-65	9.4	47
7	Mechanisms of amyloid deposition in Alzheimer's disease. *Annals of the New York Academy of Sciences*, **1991**, 640, 129-39	6.5	47
6	A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer's disease. *Biochemistry*, **1991**, 30, 10795-9	3.2	72
5	Hypothalamic atrial natriuretic peptide secretion plasticity: differential modulation of alpha and beta adrenoceptors. *Neuroendocrinology*, **1990**, 52, 65-9	5.6	9
4	The amyloid precursor protein of Alzheimer's disease is released by human platelets. *Journal of Biological Chemistry*, **1990**, 265, 15977-83	5.4	223
3	Parallels between the Redox Properties and Toxicity of A in Alzheimer's Disease and Mutant Cu/Zn-SOD in Familial Amyotrophic Lateral Sclerosis393-406		
2	Disrupted copper availability in sporadic ALS: Implications for CuII(atsm) as a treatment option		3
1	Ferrous-glutathione coupling mediates ferroptosis and frailty in Caenorhabditis elegans		2